Biomea Fusion, Inc. (BMEA)

NASDAQ: BMEA · IEX Real-Time Price · USD
10.13
+0.05 (0.50%)
Oct 4, 2022 4:00 PM EDT - Market closed
0.50%
Market Cap 287.88M
Revenue (ttm) n/a
Net Income (ttm) -60.94M
Shares Out 28.42M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,064
Open 10.42
Previous Close 10.08
Day's Range 9.98 - 10.44
52-Week Range 2.84 - 14.20
Beta n/a
Analysts Buy
Price Target 20.66 (+103.9%)
Earnings Date Aug 10, 2022

About BMEA

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California. [Read more...]

Industry Biotechnology
IPO Date Apr 16, 2021
Employees 72
Stock Exchange NASDAQ
Ticker Symbol BMEA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price forecast is 20.66, which is an increase of 103.95% from the latest price.

Price Target
$20.66
(103.95% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in An...

REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molec...

1 week ago - GlobeNewsWire

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeti...

REDWOOD CITY, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molec...

2 weeks ago - GlobeNewsWire

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF...

REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecu...

1 month ago - GlobeNewsWire

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecu...

2 months ago - GlobeNewsWire

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meetin...

REDWOOD CITY, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecu...

3 months ago - GlobeNewsWire

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

REDWOOD CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in the MM cohort of COVALENT-101, the company...

3 months ago - GlobeNewsWire

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219's Potential as an Oral, Long-Acting Trea...

REDWOOD CITY, Calif., June 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecu...

4 months ago - GlobeNewsWire

Biomea Fusion to Participate in Jefferies Healthcare Conference

REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecu...

4 months ago - GlobeNewsWire

Biomea Fusion to Present New Preclinical Data Showing BMF-219's Strong Activity in Relapsed/Refractory Chronic Lympho...

REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecul...

4 months ago - GlobeNewsWire

Biomea Fusion to Attend H.C. Wainwright Global Investment Conference

REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecul...

4 months ago - GlobeNewsWire

Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecul...

4 months ago - GlobeNewsWire

Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecul...

4 months ago - GlobeNewsWire

Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molec...

5 months ago - GlobeNewsWire

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molec...

5 months ago - GlobeNewsWire

Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 8...

REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel covalent small...

5 months ago - GlobeNewsWire

Biomea Fusion to Present at Oppenheimer's 32nd Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible c...

6 months ago - GlobeNewsWire

Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022

REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible c...

6 months ago - GlobeNewsWire

Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma...

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irr...

6 months ago - GlobeNewsWire

Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

7 months ago - GlobeNewsWire

Should You Buy Biomea Fusion (BMEA) Ahead of Earnings?

Biomea Fusion (BMEA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer

REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

8 months ago - GlobeNewsWire

Biomea Fusion Announces First Patient Dosed

REDWOOD CITY, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in its Phase I clinical trial evaluating BMF-...

8 months ago - GlobeNewsWire

Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference

REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

8 months ago - GlobeNewsWire

Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and i...

REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

8 months ago - GlobeNewsWire

Biomea Fusion Moves into New Headquarters and Expands R&D Facility

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irre...

9 months ago - GlobeNewsWire